USPTO serial 79430782
KNOTBODY
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 21, 2026
- Examiner
- TRUSILO, KELLY JEAN
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with KNOTBODY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for use in industry and science; biochemicals, namely, polypeptides and engineered antibodies for scientific, laboratory or research purposes; polypeptides and engineered antibodies for use in the manufacture of pharmaceuticals and drugs; ion channel modulating or G-protein-coupled receptor modulating engineered antibodies, including antagonists or agonists for scientific, laboratory or research purposes; ion channel modulating or G-protein-coupled receptor modulating engineered antibodies, including antagonists or agonists for use in the manufacture of pharmaceuticals and drugs; engineered antibodies being antagonists or agonists for modulating G-protein-coupled receptors (GPCRs) for scientific, laboratory or research purposes; engineered antibodies being antagonists or agonists for modulating G-protein-coupled receptors (GPCRs) for use in the manufacture of pharmaceuticals and drugs; engineered antibodies derived from mini-protein toxins for scientific, laboratory or research purposes; engineered antibodies derived from mini-protein toxins for use in the manufacture of pharmaceuticals and drugs | ACTIVE | — |
| 005 | Pharmaceuticals and pharmaceutical preparations for the treatment of diseases and conditions associated with dysregulation of ion channel or G-protein-coupled receptor activity, including preparations for the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; drugs for the treatment of diseases and conditions associated with dysregulation of ion channel or G-protein-coupled receptor activity, including preparations for the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; engineered antibodies for medical use; pharmaceuticals, drugs and pharmaceutical preparations incorporating engineered antibodies, ion channel modulating engineered antibodies including antagonists or agonists, engineered antibodies being antagonists or agonists for modulating G-protein-coupled receptors (GPCRs) or engineered antibodies derived from mini-protein toxins for the treatment of diseases and conditions associated with dysregulation of ion channel or G-protein-coupled receptor activity, including those for the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; vaccines | ACTIVE | — |
| 042 | Scientific and technological services namely scientific research, analysis and testing in the fields of pharmaceuticals, biochemicals, polypeptides, antibodies, ion channel modulating or G-protein-coupled receptor modulating antibodies and antibodies derived from mini-protein toxins; drug discovery and drug development services; conducting or providing research and development services for others in the field of antibodies; scientific and medical research laboratory services relating to the production of antibodies, ion channel modulating antibodies including antagonists or agonists, antibodies being antagonists or agonists for modulating G-protein-coupled receptors (GPCRs) or antibodies derived from mini-protein toxins; antibody engineering; scientific research services relating to the discovery, preclinical and clinical development of therapeutic products; information, advisory and consultancy services in relation to all of the aforesaid | ACTIVE | — |
| 044 | Medical services; medical testing, analysis and diagnostic services in the field of antibodies; medical services connected with the treatment of diseases through the use of antibodies, ion channel modulating antibodies including antagonists or agonists, antibodies being antagonists or agonists for modulating G-protein-coupled receptors (GPCRs) or antibodies derived from mini-protein toxins, or pharmaceuticals, drugs and pharmaceutical preparations derived from the aforesaid; information, advisory and consultancy services in relation to all of the aforesaid | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Maxion Therapeutics Limited
- Other trademarks owned by Maxion Therapeutics Limited
- Other trademarks owned by Maxion Therapeutics Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named KNOTBODY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 21, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 21, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 21, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 3, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 3, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 25, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 7, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 5, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 5, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 5, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 1, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 18, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 18, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 12, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 11, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 10, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 25, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 25, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 21, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |